IBIO, INC. (IBIO)
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
SM Energy to Participate in Upcoming Investor Conference
Cardinal Infrastructure Group Announces Acquisition of Piedmont Pipe Construction
Arianne Phosphate Executes Joint Venture Framework Agreement with Travertine Technologies
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Aya Gold & Silver Reports High-Grade Exploration Drill Results Near Pit Depth at Zgounder
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
NIQ Launches Product Intelligence to Power AI-Driven Commerce
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
The H&H Group Continues Growth Momentum with ReposiTrak SBT 2.0